Lunsumio VELO reduces administration time from 2-4 hours to approximately one minute –– Availability of Lunsumio VELO allows ...

LONDON, UK / ACCESS Newswire / December 22, 2025 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, provides an update ...

Investigator-initiated trial aims to provide proof-of-concept for bexmarilimab in overcoming acquired resistance to checkpoint inhibitors, a major challenge for most melanoma and lung cancer patients ...

MALMÖ, SE / ACCESS Newswire / December 22, 2025 / Ascelia Pharma AB (publ) (ticker:ACE)(STO:ACE) today announces that the Nomination Committee for the Annual General Meeting (AGM) on 4 May 2026 has ...

Agreement addresses all requests by President Trump to reduce drug costs in the U.S., encourage global investment and protect ...

Neuraworx Medical Technology, Inc., a neurotechnology company developing first-in-class bioelectronic solutions for brain ...

Agreement with the U.S. government addresses prescription drug costs and encourages other wealthy nations to reward ...

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced that it has entered into a ...

After President Trump's Marijuana Executive Order, Will the DEA Act-or Be Compelled by the Courts?"Despite holding FDA Orphan Drug Designations, passing multiple DEA inspections, being awarded a DEA ...

Boards and executive buyers are raising the 2026 bar for all product and service rankings and this annual statement explains the standards Black Book applies to keep survey evaluations rigorous, ...

Thermo Fisher Scientific Inc., the world leader in serving science, today announced the enrollment of the first patient in ...

Sermo Barometer reveals shifting access pathways, evolving prescribing behavior, and long-term impacts on patient care.NEW ...